Research progress in the treatment of interstitial lung disease related to polymyositis/dermatomyositis
10.3969/j.issn.1674-8115.2024.04.015
- VernacularTitle:多发性肌炎/皮肌炎相关间质性肺病治疗的研究进展
- Author:
Xiaofeng ZHENG
1
;
Ling XU
Author Information
1. 上海交通大学医学院附属第六人民医院呼吸与危重症医学科,上海 200233
- Keywords:
polymyositis;
dermatomyositis;
interstitial lung disease;
medication
- From:
Journal of Shanghai Jiaotong University(Medical Science)
2024;44(4):531-536
- CountryChina
- Language:Chinese
-
Abstract:
Polymyositis/dermatomyositis(PM/DM)is a heterogeneous autoimmune disease characterized by inflammatory cell infiltration in skeletal muscles with unknown etiology.The incidence of interstitial lung disease(ILD)in PM/DM is higher.ILD is the most important factor affecting its prognosis.Existing evidence suggests that there is significant heterogeneity in PM/DM-related ILD,which requires individualized treatment based on the onset form,progression rate,lesion involvement range,laboratory examination,presence of adverse prognostic factors,and response to treatment of ILD.This article summarizes the research progress in the treatment of PM/DM-related ILD in recent years,including the selection of traditional therapeutic drugs,timing of medication,and new drugs attempted in this field in clinical practice(such as biological agents and Janus kinase inhibitors),intravenous immunoglobulin,anti-fibrotic drugs,and potentially effective non-drug treatment methods,aiming at providing reference for clinical doctors to formulate PM/DM-ILD treatment plans and improve patient prognosis.
